Cannara Biotech Inc. (TSXV: LOVE)
Canada
· Delayed Price · Currency is CAD 0.670
+0.080 (13.56%)
Nov 20, 2024, 3:46 PM EST
Cannara Biotech Income Statement
Financials in millions CAD. Fiscal year is September - August.
Millions CAD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | May '24 May 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | Aug '20 Aug 31, 2020 | Aug '19 Aug 31, 2019 | 2018 |
| Operating Revenue | 76.7 | 57.07 | 35.48 | 16.29 | 2.47 | 2.1 | Upgrade
|
| Other Revenue | -0.01 | 0.19 | 0.36 | 0.73 | 0.08 | - | Upgrade
|
| Revenue | 76.69 | 57.26 | 35.84 | 17.02 | 2.55 | 2.1 | Upgrade
|
| Revenue Growth (YoY) | 50.15% | 59.76% | 110.58% | 567.24% | 21.64% | 142.35% | Upgrade
|
| Cost of Revenue | 47.81 | 30.03 | 18.51 | 6.72 | 1.33 | 0.4 | Upgrade
|
| Gross Profit | 28.88 | 27.23 | 17.33 | 10.3 | 1.22 | 1.69 | Upgrade
|
| Selling, General & Admin | 16.13 | 11.77 | 9.68 | 6.98 | 8.23 | 8.86 | Upgrade
|
| Research & Development | 1.19 | 1.03 | 1.26 | 1.91 | 2.6 | - | Upgrade
|
| Operating Expenses | 20.28 | 15.51 | 12.51 | 10.24 | 13.18 | 11.62 | Upgrade
|
| Operating Income | 8.6 | 11.72 | 4.82 | 0.05 | -11.96 | -9.92 | Upgrade
|
| Interest Expense | -5.03 | -4.53 | -2.23 | -1.71 | -1.35 | -1.53 | Upgrade
|
| Interest & Investment Income | 0.19 | 0.24 | 0.09 | 0.05 | 0.27 | 0.68 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.03 | 0.07 | 0.03 | -0.11 | -0.04 | -0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.74 | -0.77 | -0.53 | -0.02 | -0.01 | -0.3 | Upgrade
|
| EBT Excluding Unusual Items | 2.99 | 6.72 | 2.18 | -1.73 | -13.1 | -11.1 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.96 | -0.13 | -0.05 | -0.07 | -0.01 | - | Upgrade
|
| Asset Writedown | - | - | - | - | -0.04 | - | Upgrade
|
| Other Unusual Items | 0.37 | 0.36 | 0.17 | 0.27 | 0.05 | -1.88 | Upgrade
|
| Pretax Income | 5.32 | 6.95 | 2.31 | -1.53 | -13.09 | -12.97 | Upgrade
|
| Earnings From Continuing Operations | 5.32 | 6.95 | 2.31 | -1.53 | -13.09 | -12.97 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.61 | 0.66 | Upgrade
|
| Net Income | 5.32 | 6.95 | 2.31 | -1.53 | -12.48 | -12.32 | Upgrade
|
| Net Income to Common | 5.32 | 6.95 | 2.31 | -1.53 | -12.48 | -12.32 | Upgrade
|
| Net Income Growth | 9.22% | 201.26% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 90 | 89 | 88 | 77 | 71 | 61 | Upgrade
|
| Shares Outstanding (Diluted) | 91 | 89 | 88 | 77 | 71 | 61 | Upgrade
|
| Shares Change (YoY) | 2.09% | 1.66% | 14.80% | 7.26% | 16.02% | 70.38% | Upgrade
|
| EPS (Basic) | 0.06 | 0.08 | 0.03 | -0.02 | -0.17 | -0.20 | Upgrade
|
| EPS (Diluted) | 0.06 | 0.08 | 0.03 | -0.10 | -0.17 | -0.20 | Upgrade
|
| EPS Growth | 7.32% | 195.77% | - | - | - | - | Upgrade
|
| Free Cash Flow | 1.15 | -4.44 | -21.55 | -33.17 | -18.51 | -30.42 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | -0.05 | -0.25 | -0.43 | -0.26 | -0.49 | Upgrade
|
| Gross Margin | 37.65% | 47.56% | 48.36% | 60.49% | 48.00% | 80.74% | Upgrade
|
| Operating Margin | 11.21% | 20.46% | 13.45% | 0.31% | -468.76% | -473.16% | Upgrade
|
| Profit Margin | 6.93% | 12.13% | 6.43% | -8.98% | -489.35% | -587.28% | Upgrade
|
| Free Cash Flow Margin | 1.50% | -7.76% | -60.11% | -194.86% | -725.49% | -1450.77% | Upgrade
|
| EBITDA | 14.29 | 16.53 | 8.62 | 2.75 | -9.72 | -9.5 | Upgrade
|
| EBITDA Margin | 18.63% | 28.87% | 24.06% | 16.18% | - | - | Upgrade
|
| D&A For EBITDA | 5.69 | 4.82 | 3.8 | 2.7 | 2.24 | 0.43 | Upgrade
|
| EBIT | 8.6 | 11.72 | 4.82 | 0.05 | -11.96 | -9.92 | Upgrade
|
| EBIT Margin | 11.21% | 20.46% | 13.45% | 0.31% | - | - | Upgrade
|
| Revenue as Reported | 76.99 | 57.56 | 36 | 17.27 | 2.58 | 2.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.